TO THE EDITOR
Leukemias are characterized by deregulation of hematopoietic cell differentiation and/or resistance to apoptosis. Among proteins involved in regulation of these pathways and suspected to play an important role in leukemogenesis are the Jak and STAT proteins. STAT (signal transducer and activator of transcription) 5a and STAT5b proteins are latent cytoplasmic transcription factors that translocate to the nucleus upon activation by cytoplasmic Jak tyrosine kinases. They participate in elemental cell biologic processes, including cellular growth, cell cycle progression and apoptosis. Based on several reports of STAT5 constitutive activation in leukemic cells, it has been hypothesized that STAT5 proteins may play an important role in leukemia.
We previously reported on an original fusion protein between STAT5b and RARa in a patient with Acute Promyelocytic-Like phenotype, 1 and we demonstrated that STAT5b gene rearrangement is rare in primary human hematologic malignancies. 2 We decided on investigating the subcellular distribution of STAT5 proteins upon leukemia cells by immunochemistry experiments because the previous studies exclusively analyzed the STAT proteins in leukemias by Western blotting and electro mobility shift assay (EMSA) experiments on total nuclear protein extracts. 3 Mononuclear cells from bone marrow or peripheral blood containing more than 80% blasts were isolated from 70 untreated patients with primary leukemias at initial diagnosis and STAT5 subcellular distribution was analyzed by indirect immunofluorescence with polyclonal antibodies directed against either STAT5a (L20), STAT5b (C17) or both STAT5a/b (N20) proteins. As summarized in Table 1 , STAT5 nuclear distribution has been observed in 39/59 (67%) acute myeloblastic leukemia (AML) cases. Moreover, we have detected a nuclear localization of the STAT5 proteins in all chronic myelogenous leukemia (CML) and AML5 tested. Surprisingly, we pointed out a subnuclear localization for STAT5 proteins in AML5 (4/4), CML (4/5), AML2 (1/18) and in the K562 cell line expressing Bcr-Abl (Figure 1 ). In order to determine the precise subnuclear localization of the STAT5 proteins, we performed a double labelling experiment with both a polyclonal antibody to the a and b forms of STAT5a/b (N20) and a monoclonal antibody to Nucleolin/C23. A nucleolar colocalization of STAT5 with the nucleolin/C23 protein was observed ( Figure 1 ). This is, to our knowledge, the first evidence of a nucleolar translocation of STAT transcription factors in hematological malignancies. Interestingly, we observed two different patterns of STAT5 subnuclear distribution in the K562 cells. Whereas STAT5 proteins revealed by an antibody directed against the highly homologous N-terminus domain of both STAT5a and STAT5b under a and b forms are located within the nuclei and the nucleoli, immunostaining with antibobies directed against the C-terminal domains of STAT5ba (C17) and STAT5aa (L20) revealed a distribution in the whole nucleus but not in the nucleoli as revealed by a total absence of co-localization with Nucleolin/C23. This pattern of nuclear distribution could be explained by a nucleolar localization of C-terminal truncated b forms of both STAT5a and STAT5b. Truncated STAT5 proteins lacking the transactivation domain have been observed in physiological conditions. These shorter b forms retain DNA binding ability but do not induce subsequent transcriptional activity. 4 We thus hypothesized that the nucleolar STAT5 proteins might correspond to the truncated b forms of these transcription factors. We next tried to determine if nucleolar localization is a common event following activation of STAT5 proteins.
We reported no evidence for STAT5 nucleolar distribution in activated peripheral blood mononuclear cells nor in lymphocytic U937, megacaryocytic MEG-01, Jurkat or in nonhematopoietic HeLa cell lines (data not shown). We demonstrated a nucleolar repartition of STAT5b isoforms only in K562 cells. This result raised the possibility that the nucleolar localization of STAT5 is part of the leukemogenic phenotype in CML.
Several studies reported a STAT5 activation by BCR-ABL fusion protein in CML cells. 5 We thus tested the contribution of the oncogenic tyrosine kinase BCR-ABL on the nucleolar localization of STAT5 proteins using a treatment with the kinase inhibitor STI571.
6 K562 cells were treated with 1 mmol/l STI571, for 24-72 h. Western blot analysis of nuclear protein extracts from untreated or STI571 treated cells showed a dramatic decrease in STAT5ab phosphorylation but immunocytochemical analysis revealed that STI571 treatment of K562 cells did not affect the STAT5 nucleolar localization (data not shown). These results indicate that the oncogenic tyrosine kinase BCR-ABL is probably not responsible for STAT5 nucleolar localization.
The nucleolus is a highly dynamic structure containing a large number of proteins and exhibiting a constant flow of RNA and proteins. Apart from its well-known involvement in the rRNA biogenesis, the nucleolus seems to be involved in the regulation of proteasome-dependent protein degradation. It has been proposed that trafficking through the nucleoli might be involved in protein turn-over. Recent data on STAT5 turn over analysis have revealed that proteasome inhibition stabilize the phosphorylated form of STAT5. Wang et al 7 demonstrated that tyrosine phosphorylated b forms of STAT5 are considerably more stable than native tyrosine phosphorylated forms and are resistant to proteasome-mediated degradation. Thus, it could be hypothesized that the nuclear accumulation of more stable STAT5a/b b isoforms result in nucleolar translocation as it has previously been shown that overexpressed proteins accumulate in nucleolus. According to this hypothesis we demonstrated that the nucleolar translocation of both proteins is due to already existing proteins in the nucleoplasm as protein biogenesis inhibition by cycloheximide treatment did not affect their nucleolar distribution (data not shown). However, our experiments of proteasome inhibition by an MG132 treatment based method indicate that the nucleolar distribution of STAT5 in K562 cells is not a consequence of proteasome-dependent degradation of both STAT5a and STAT5b proteins (data not shown).
STAT proteins are nucleocytoplasmic shuttling transcription factors that translocate to the nucleus after cytokine-dependent tyrosine phosphorylation and subsequent dimerisation. STATs are thought to translocate back to the cytoplasm after dephosphorylation. However, the mechanisms regulating the subcellular distribution of STATs are not well understood. Recently, Zeng et al provided a model for STAT5b nucleocytoplasmic translocation implicating two different import and an export mechanisms. They demonstrated a continuous nucleocytoplasmic cytokine-independent shuttling of the nonphosphorylated monomeric form of STAT5b that is rapidly exported by the CRM1/exportin 1-mediated nuclear export receptor. After cytokine stimulation STAT5b is phosphorylated, dimerises and translocates to the nucleus. Upon dimerisation the region responsible for the CRM1-dependent nuclear export is masked leading to nuclear accumulation of the dimerized transcription factors. The dephosphorylation leads to monomerization of STAT5b and CRM1-mediated translocation back to the cytoplasm. 8 In this context we could hypothesize that nucleolar localization of STAT5 isoforms could be the result of a STAT5 nuclear accumulation due to defect in nuclear export, either by defect in the CRM1-dependent nuclear export machinery or by a sustained inactive dimeric form of STAT5b that could not be exported.
Further investigations are necessary for a better understanding of the mechanisms that lead to the nucleolar distribution of STAT5 transcription factors in AML and its potential implication in the leukemic phenotype. Cytologie, CHU Nancy-Brabois, France
